Cure Pharmaceutical Corporation
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
1
Ending by 2030
Apr 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 17, 2027The maintenance fee for Thin film with high load of active ingredient (US 10,413,516) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Apr 30, 2027The maintenance fee for Method for obtaining an extract of a plant biomass (US 11,801,278) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for Protein-polysaccharide macromolecular complex article of manufacture containing encapsulated ethyl alcohol (US 10,470,478) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Jun 26, 2027The maintenance fee for Methods and compositions for improving sleep (US 11,850,242) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Oral dissolvable film containing vitamin D3 (US 11,857,557) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,999,372 | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,470,478 | Protein-polysaccharide macromolecular complex article of manufacture containing encapsulated ethyl alcohol In force · From the USPTO record | In force | From the USPTO record | |
| US 11,160,292 | Protein-polysaccharide macromolecular complex article of manufacture containing encapsulated ethyl alcohol In force · From the USPTO record | In force | From the USPTO record | |
| US 10,413,516 | Thin film with high load of active ingredient In force · From the USPTO record | In force | From the USPTO record | |
| US 11,850,242 | Methods and compositions for improving sleep In force · From the USPTO record | In force | From the USPTO record | |
| US 11,179,331 | Oral soluble film containing sildenafil citrate In force · From the USPTO record | In force | From the USPTO record | |
| US 11,857,557 | Oral dissolvable film containing vitamin D3 In force · From the USPTO record | In force | From the USPTO record | |
| US 11,801,278 | Method for obtaining an extract of a plant biomass In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 8: 11 patents in force now held by others · 8 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 9 no status recorded